A phase II trial with a safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma
A Study of the Addition of APX005M to Doxorubicin in Patients with Advanced Sarcoma
Sponsor: Apexigen
Enrolling: Male and Female Patients
IRB Number: AAAS0095
U.S. Govt. ID: NCT03719430
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness of a new investigational drug, APX005M, used in combination with the standard (or usual) treatment for these types of sarcoma. The standard treatment is doxorubicin (a chemotherapy) and olaratumab (a targeted drug which works against a protein that makes sarcomas grow). The investigators believe that doxorubicin and olaratumab, the standard treatment, may work better when combined with APX005M. The purpose of this clinical trial is to evaluate the safety of doxorubicin, olaratumab, and APX005M when used together, and to see if this study treatment is effective for patients with Dedifferentiated liposarcoma, Leiomyosarcoma, and Undifferentiated pleomorphic sarcoma.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with soft tissue sarcoma? Yes No
Do you have no history of active autoimmune disease? Yes No
Do you have measurable disease? Yes No
Do you have adequate cardiac and bone marrow function? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162